Vivimed Labs Approves Audited FY26 Results Amidst CIRP

Vivimed Labs Ltd announced that its Board of Directors, operating under the Interim Resolution Professional (IRP) due to Corporate Insolvency Resolution Process (CIRP), has approved the audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated net loss of ₹1,716.11 Lakhs for the year ended March 31, 2026, a significant increase from the previous year's loss. Revenue from operations for the year stood at ₹103.60 Crores. The company continues to operate on a going concern basis, supported by management's belief in future operational improvements and promoter support, despite ongoing investigations and the CIRP proceedings initiated by a vendor.